Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04549155 · ClinicalTrials.gov registry record · NA
Network-guided TMS in Early Alzheimer's Disease
A NA study, sponsored by Duke University.
- Completed
- Registry status
- NA
- Development phase
- 37
- Enrollment target
NCT04549155: Completed NA study, sponsored by Duke University.
NCT04549155 is a NA study that has completed, run by Duke University. The registered enrollment target is 37 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04549155, a NA study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- NA
- Development phase
- 37 participants
- Enrollment target
Study Summary
The proposed research will test a novel network-based neurostimulation approach using MRI-derived measures of brain connectivity to establish target sites for neurostimulation and test for the enhancement of memory function beyond a sham stimulation condition. This will be tested in cohort of MCI adults using network-based transcranial magnetic stimulation (TMS) to assess for behavioral improvement due to the controlled intervention. This study will provide important evidence towards the efficacy of neuromodulatory treatments for memory decline and will accelerate the discovery of potent non-invasive treatments to remediate cognitive decline in cognitively impaired older adults.
Primary Outcome
The primary outcome measure is the difference in memory accuracy between TMS conditions (active vs. sham) on a word memory task. We will rely on a validated EM task that has shown (1) reliable activation of the Memory Success Network (MSN), and (2) reliable deficits in MCIs. During each block of the Encoding phase, participants read a list of 120 English words and perform a domain judgement (living/nonliving) during both network-based and standard TMS targets. Active and sham TMS trials are inte
Interventions
- DEVICE Transcranial Magnetic Stimulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 37 participants |
| Start Date | 2022-03-08 |
| Est. Completion | 2025-06-27 |
| Phase | NA |
What the finished NCT04549155 record still lists
NCT04549155 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 37 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (97% lower).
The record links to 0 conditions, and to 1 intervention - of which Transcranial Magnetic Stimulation is the first listed.
NCT04549155 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04549155 about?
NCT04549155 is a clinical study titled "Network-guided TMS in Early Alzheimer's Disease". The proposed research will test a novel network-based neurostimulation approach using MRI-derived measures of brain connectivity to establish target sites for neurostimulation and test for the enhancement of memory function beyond a sham stimulation condition. This will be tested in cohort of MCI ad...
What is the current status of trial NCT04549155?
This trial is currently completed. It is a NA study. The enrollment target is 37 participants. The study started on 2022-03-08. Estimated completion is 2025-06-27.
What interventions are being tested in trial NCT04549155?
The interventions under investigation include: Transcranial Magnetic Stimulation (DEVICE).
Who is sponsoring clinical trial NCT04549155?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04549155's enrollment target sits among peer trials
37 1540th of 2000 higher than 460 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02800486 · 37 participants · Phase 2
Super Selective Intra-arterial Repeated Infusion of Cetuximab (Erbitux) With Reirradiation for Treatment of Relapsed/Refractory GBM, AA, and AOA
- NCT03173937 · 37 participants · Phase 1
Unrelated Umbilical Cord Blood Transplantation for Severe Aplastic Anemia and Hypo-plastic MDS Using CordIn(TM), Umbilical Cord Blood-Derived Ex Vivo Expanded Stem and Progenitor Cells to Expedite Engraftment and Improve Transplant Outcome
- NCT03295227 · 37 participants · Phase 1
Pembrolizumab in Treating Participants With Unresectable Thymoma or Thymic Cancer
- NCT03401047 · 37 participants · Early Phase 1
Study to Assess Potential Impairments in Estradiol Augmentation of Gonadotropin Secretion in Polycystic Ovary Syndrome
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI